Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bicycle Therapeutics Ltd.

Two-wheeled constrained peptides

This article was originally published in Start Up

Executive Summary

Natural peptides have plenty of drawbacks that have held them back when it comes to pharmaceutical applications: their highly unstable amino acid chains degrade too quickly to produce a therapeutic effect, discovery has been difficult to industrialize, and manufacturing complex and costly. However, emerging technologies for synthetically stabilizing peptide structures may eventually conquer most of natural peptides’ drawbacks as pharmaceuticals. Bicycle Therapeutics Ltd. hopes its two-wheel “constrained” peptides it calls “bicycles” will ride off with the prize for exploiting nature’s medicines.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel